Brief: Virpax Pharmaceuticals - Completes All FDA-Required Pre-Clinical Studies For Epoladerm
22/03/2022 13:26
March 22 (Reuters) - Virpax Pharmaceuticals Inc VRPX.O :
* VIRPAX PHARMACEUTICALS - COMPLETES ALL FDA-REQUIRED
PRE-CLINICAL
STUDIES FOR EPOLADERM
* VIRPAX PHARMACEUTICALS - PILOT STUDY TO TAKE PLACE IN
CANADA
UNDER CTA FILING WITH ENROLLMENT OF FIRST PATIENT ANTICIPATED IN
2022
Source text for Eikon: ID:nBwsHKYSa
Further company coverage: VRPX.O
Recent news on Virpax Pharmaceuticals
See all newsVirpax Pharma plunges as Nasdaq delisting looms
Brief: Virpax Pharmaceuticals Files For Offering On Best Efforts Basis Up To 2.4 Million Shares Of Common Stock
Brief: Virpax receives positive Probudur™ results for dose range study
Brief: Virpax Looking To Use Met To Develop Intranasal Covid Vaccine
Brief: Virpax Confirms Positive Results With Us Army With Probudur™ For Combat Care Study